Although recent supply chain disruptions, pricing upheavals, and investor uncertainty have negatively impacted IPOs and M&A activity, artificial intelligence is fueling innovation and transforming drug discovery and clinical development for life sciences companies.

In this Industry Pulse, gain a comprehensive view of the current state of the life sciences industry, the challenges facing pharmaceutical manufacturers, and the new technologies that are driving investment opportunities and changing the long-term strategies of life sciences companies.

Read this Industry Pulse to learn more about:

• What Q2 2025 of the biopharmaceutical market signals for the future
• Healthcare policy changes under Trump
• Driving value from the IPO process in life sciences
• Creating a long-term, competitive biomanufacturing strategy

​